Navigation Links
NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011
Date:4/6/2011

Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida. NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos-related pulmonary cancer, a promising treatment strategy for glioblastomas, genome-wide mapping of nickel-related cancer and greater understanding of melanoma and bladder cancer.

Detection of Mesothelioma in Asbestos Exposed Individuals with Aptamer Proteomic Technology
Author: Harvey I. Pass, MD, professor, Cardiothoracic Surgery and Surgery

Malignant pleural mesothelioma is an aggressive, asbestos-related pulmonary cancer that develops in the lining of the lungs. Researchers investigated a novel protein test to detect early-stage, asbestos-related pulmonary cancer. The new test can accurately identify proteins secreted from cancerous tumors caused by asbestos exposure. In a blinded test researchers detected 15 of 19 cases of stage 1 or stage 2 malignant pleural mesothelioma. The goal of the new diagnostic test is to find the cancer early enough to effectively treat it. The test called "Multiplex SOMAmer Assay" by SomaLogic, Inc. uses SOMAmers, chemically modified single-stranded DNA molecules to bind specifically to target proteins and quantify biomarkers. The test successfully measures 19 protein biomarkers for malignant pleural mesothelioma and quantifies the small amount of proteins secreted by tumor cells.

Abstract 2812: Monday, April 4, 2011, 8:30 AM
Learn more : http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3143326d-b0b1-4408-9077-09ac88372faa&cKey=13dffe63-f569-45c7-ab9d-26c8e6bf
'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Soy isoflavones not a risk for breast cancer survivors
2. Nanopolymer shows promise for helping reduce cancer side effects
3. Early cancer treatment successes lead to CAREER Award for Rafael Davalos
4. Discovery of protein that alters nutrition of breast cancer cells
5. Extreme weight gain raises risk for recurrence among breast cancer survivors
6. High dose of oxygen enhances natural cancer treatment
7. Nicotine does not promote lung cancer growth in mouse models
8. Lung cancer risk rises in the presence of HPV antibodies
9. Target for lung cancer chemoprevention identified
10. DNA of 50 breast cancer patients decoded
11. Jan-Åke Gustafsson leads team with $5.2M for prostate cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... September 5, 2013, Shenzhen, China BGI in collaboration ... other Chinese institutes, have completed the genome sequencing of ... infectious disease tuberculosis (TB). The study published online in ... researchers to better understand the genetic basis underlying drug ...
... industry and cities, coupled with a rising world shortage of ... increase in the use of treated wastewater for farming and ... -- comparable in North America alone to the volume of ... in many nations, not even quantified. Of ...
... Mexico, Rocky Mountain juniper ( Juniperus scopulorum Sarg .) ... The juniper,s woodhighly valued for its durability, rich color, ... furniture, and fence posts. For centuries, the leaves and ... essential oil, have been used extensively by native people ...
Cached Biology News:Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 2UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 3UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 4UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 5UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 6UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 7UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 8UN: Rising reuse of wastewater in forecast but world lacks data on 'massive potential resource' 9
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The ... based not-for-profit organization, is pleased to announce they are ... Trials Day. These donations represent the effort and commitment ... at the GGI partner sites in 2014. , ... the greater good of clinical trial participation, GGI supports ...
(Date:5/20/2015)... May 20, 2015  OncoSec Medical Inc. ("OncoSec") ... immunotherapies, will present data from ongoing clinical and ... Sciences, Emerging Approaches to Cancer Immunotherapy. OncoSec,s Chief ... and Chief Medical Officer Mai. H. Le, MD, ... Plasmid IL-12 Can Increase CD8 TILs and Drive ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 2OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 3OncoSec Medical to Present Data at the New York Academy of Sciences' Cancer Immunotherapy Symposium 4
... and long-term disease-free survival of breast cancer patients; ... April 23 Clarient, Inc. ... anatomic pathology and molecular testing services resource for ... that it has been granted an exclusive intellectual ...
... , - Strong 10.3% Growth ... the world leader in ophthalmic optics, today,announced consolidated revenue of ... a reported 10.3% increase on the first quarter,of 2008. Excluding ... Despite contracting demand early in the ...
... today the opening,ceremony of its new active pharmaceutical ingredient ... to take over the site that,had been manufacturing Lipitor(R) ... April 6th and the transaction closed on the 8th; ... of manufacture for Pfizer but,will mostly make use of ...
Cached Biology Technology:Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 2Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 3Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 4Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation 5Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3
... The economical ICS-90 uses continuous chemical suppression ... give you fast, accurate determinations of common ... Easy to operate, quick to equilibrate, and ... compact ICS-90 helps you achieve maximum sample ...
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
... 400 unique human proteins on a ... proteins, all extracellular proteins (EP) according ... in quadruplicate for high-quality results. Additional ... layout guarantee high validity and reproducibility., ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: